Gossamer Bio (GOSS) EBT (2018 - 2026)

Gossamer Bio has reported EBT for 9 years, with the latest figure at -$28.5 million in Q2 2026.

• On a quarterly basis, EBT rose 25.51% year-over-year to -$28.5 million in Q2 2026; TTM through Jun 2026 was -$171.3 million, a 18.23% decrease from a year earlier, with the FY2025 full-year figure at -$170.5 million, down 206.39% from the prior year.
• EBT was -$28.5 million for Q2 2026 at Gossamer Bio, up from -$47.3 million in the prior quarter.
• The five-year high for EBT was $53.7 million in Q2 2024, with the low at -$59.0 million in Q3 2022.
• Average EBT over 5 years is -$40.0 million, with a median of -$46.0 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: EBT soared 226.29% in 2024, then tumbled 171.32% in 2025.
• Over 5 years, EBT stood at -$57.2 million in 2022, then climbed by 15.85% to -$48.1 million in 2023, then gained by 26.4% to -$35.4 million in 2024, then sank by 33.54% to -$47.3 million in 2025, then surged by 39.76% to -$28.5 million in 2026.
• The last three EBT figures came in at -$28.5 million (Q2 2026), -$47.3 million (Q1 2026), and -$47.3 million (Q4 2025), per Business Quant data.